|
|
https://mb.cision.com/Public/18595/logo/86a99b25f755738d_org.jpg
UCB to license its AI technology that improves identification of Osteopo=
rosis to ImageBiopsy Lab
=C2=B7 ImageBiopsy Lab will further develop and launch an AIbased fracture=
identification tool based on UCBdeveloped BoneBot AI technology which det=
ects the presence of =E2=80=9Csilent=E2=80=9D or asymptomatic fractures... See more |
|
|
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/logo/86a99b25f755738d_org.jpg
Disposals of own shares
Brussels Belgium, 18 October 2021 =E2=80=93 20:00 CEST =E2=80=93 regula=
ted information
Disposal of own shares
In accordance with article 8:6 of the Royal Decree executing the Belgian Co=
de of Companies and Associations, UCB announces that, following exercises o=
f stock options by members... See more |
|
|
|
| |
|
| |
|
|
Dans le cadre du programme de Rachat d'actions propres autorisé par l'Assemblée Générale des actionnaires le 19 mai 2020, Econocom Group SE a procédé, durant la période du 11/10/2021 au 17/10/2021, aux transactions suivantes sur l'action Econocom Group :
Date
M&eacut... See more |
|
|
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/logo/86a99b25f755738d_org.jpg
Update on U.S. FDA Review of Biologics License Application BLA for bim=
ekizumab
=C2=B7 The U.S. FDA has informed UCB via letter that the Agency was=C2=A0un=
able to complete review of the BLA for bimekizumab by the PDUFA date and is=
deferring action on the application
=C2=B7 The Agency cited only the inability to... See more |
|
|
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/logo/86a99b25f755738d_org.jpg
Update on U.S. FDA Review of Biologics License Application BLA for bim=
ekizumab
=C2=B7 The U.S. FDA has informed UCB via letter that the Agency were unable=
to complete review of the BLA for bimekizumab by the PDUFA date and is def=
erring action on the application
=C2=B7 The Agency cited only the inability to conduct... See more |
|
|
|
| |
|
| |
|
|
Search :
